We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL.
- Authors
Langerbeins, P.; Robrecht, S.; Nieper, P.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; Fink, A.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Schneider, C.; Müller, L.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M.; Zahn, M.; Dörfel, S.
- Abstract
B Conclusions: b Early ibrutinib-treatment of patients with asymptomatic Binet stage A CLL at high risk of progression failed to demonstrate an overall survival benefit when compared to placebo. B Introduction: b We present the final analysis of the phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk of progression defined by a comprehensive score (NCT02863718).
- Subjects
CHRONIC lymphocytic leukemia; ASYMPTOMATIC patients; PLACEBOS; RICHTER syndrome
- Publication
Hematological Oncology, 2023, Vol 41, p56
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_24